top of page

Eveliqure announces the start of a Phase 1 clinical study of its combined Shigella and ETEC vaccine

  • EVI
  • Sep 24, 2020
  • 1 min read

Eveliqure and the SHIGETECVAX consortium announce today the initiation of clinical testing for the ShigETEC vaccine candidate, with the dosing of the first subject in a Phase 1 safety and immunogenicity study in Europe. ShigETEC is an orally administered vaccine candidate developed by Eveliqure. The vaccine targets Shigella and Enterotoxigenic E. coli (ETEC), two of the major pathogens responsible for diarrhoeal diseases in travellers to endemic countries, as well as a major threat to children living in low- and middle- income countries.



Comments


Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

Thanks for subscribing! If you have any questions or would like to unsubscribe contact us at communication@euvaccine.eu.

  • LinkedIn - White Circle
  • Twitter - White Circle
EU emblem_flag_yellow_high (1).jpg

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

© 2024 European Vaccine Initiative. Designed by European Vaccine Initiative

bottom of page